FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:468-475 August 12, 1999 Number 7 Next

	Full Text PDF Editorial by Adkinson, N. F. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment.

Methods We conducted a randomized, double-blind, placebo-controlled trial of the discontinuation of immunotherapy for grass-pollen allergy in patients in whom three to four years of this treatment had previously been shown to be effective. During the three years of this trial, primary outcome measures were scores for seasonal symptoms and the use of rescue medication. Objective measures included the immediate conjunctival response and the immediate and late skin responses to allergen challenge. Cutaneous-biopsy specimens obtained 24 hours after intradermal allergen challenge were examined for T-cell infiltration and the presence of cytokine-producing T helper cells (T_H2 cells) (as evidenced by the presence of interleukin-4 messenger RNA). A matched group of patients with hay fever who had not received immunotherapy was followed as a control for the natural course of the disease.

Results Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it. Symptom scores in both treatment groups (median areas under the curve in 1995, 921 for continuation of immunotherapy and 504 for discontinuation of immunotherapy; P=0.60) were markedly lower than those in the group that had not received immunotherapy (median value in 1995, 2863). Although there was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression.

Conclusions Immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity.

Source Information

From the Department of Upper Respiratory Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London (S.R.D., S.M.W., E.-M.V., M.R.J., F.O., W.N., S.J.T., K.T.N.-A.); the Allergy Clinic, Royal Brompton and Harefield National Health Service Trust, London (S.R.D., S.M.W.); and Meakins Christie Laboratories, McGill University, Montreal (Q.A.H.).

Address reprint requests to Dr. Durham at the Department of Upper Respiratory Medicine, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse St., London SW3 6LY, United Kingdom, or at s.durham{at}rbh.nthames.nhs.uk.

Full Text of this Article

Related Letters:

Clinical Efficacy of Grass-Pollen Immunotherapy
Østergaard M. S., Witt K., Longo G., Barbi E., Durham S. R., Walker S. M., Varga E.-M.
Extract | Full Text  
N Engl J Med 2000; 342:58-59, Jan 6, 2000. Correspondence

This article has been cited by other articles:

• Westritschnig, K., Linhart, B., Focke-Tejkl, M., Pavkov, T., Keller, W., Ball, T., Mari, A., Hartl, A., Stocklinger, A., Scheiblhofer, S., Thalhamer, J., Ferreira, F., Vieths, S., Vogel, L., Bohm, A., Valent, P., Valenta, R. (2007). A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin. J. Immunol. 179: 7624-7634 [Abstract] [Full Text]  
• Pree, I., Reisinger, J., Focke, M., Vrtala, S., Pauli, G., van Hage, M., Cromwell, O., Gadermaier, E., Egger, C., Reider, N., Horak, F., Valenta, R., Niederberger, V. (2007). Analysis of Epitope-Specific Immune Responses Induced by Vaccination with Structurally Folded and Unfolded Recombinant Bet v 1 Allergen Derivatives in Man. J. Immunol. 179: 5309-5316 [Abstract] [Full Text]  
• Nagato, T., Kobayashi, H., Yanai, M., Sato, K., Aoki, N., Oikawa, K., Kimura, S., Abe, Y., Celis, E., Harabuchi, Y., Tateno, M. (2007). Functional Analysis of Birch Pollen Allergen Bet v 1-Specific Regulatory T Cells. J. Immunol. 178: 1189-1198 [Abstract] [Full Text]  
• Creticos, P. S., Schroeder, J. T., Hamilton, R. G., Balcer-Whaley, S. L., Khattignavong, A. P., Lindblad, R., Li, H., Coffman, R., Seyfert, V., Eiden, J. J., Broide, D., the Immune Tolerance Network Group, (2006). Immunotherapy with a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis. NEJM 355: 1445-1455 [Abstract] [Full Text]  
• Finkelman, M. A., Lempitski, S. J., Slater, J. E. (2006). {beta}-Glucans in standardized allergen extracts. Innate Immunity 12: 241-245 [Abstract]  
• Plaut, M., Valentine, M. D. (2005). Allergic rhinitis.. NEJM 353: 1934-1944 [Full Text]  
• van Oosterhout, A. J. M., Bloksma, N. (2005). Regulatory T-lymphocytes in asthma. Eur Respir J 26: 918-932 [Abstract] [Full Text]  
• Holgate, S T, Lack, G (2005). Improving the management of atopic disease. Arch. Dis. Child. 90: 826-831 [Abstract] [Full Text]  
• Holm, J., Gajhede, M., Ferreras, M., Henriksen, A., Ipsen, H., Larsen, J. N., Lund, L., Jacobi, H., Millner, A., Wurtzen, P. A., Spangfort, M. D. (2004). Allergy Vaccine Engineering: Epitope Modulation of Recombinant Bet v 1 Reduces IgE Binding but Retains Protein Folding Pattern for Induction of Protective Blocking-Antibody Responses. J. Immunol. 173: 5258-5267 [Abstract] [Full Text]  
• Niederberger, V., Horak, F., Vrtala, S., Spitzauer, S., Krauth, M.-T., Valent, P., Reisinger, J., Pelzmann, M., Hayek, B., Kronqvist, M., Gafvelin, G., Gronlund, H., Purohit, A., Suck, R., Fiebig, H., Cromwell, O., Pauli, G., van Hage-Hamsten, M., Valenta, R. (2004). Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101: 14677-14682 [Abstract] [Full Text]  
• Robinson, D S (2004). Regulation: the art of control? Regulatory T cells and asthma and allergy. Thorax 59: 640-643 [Full Text]  
• Akdis, M., Verhagen, J., Taylor, A., Karamloo, F., Karagiannidis, C., Crameri, R., Thunberg, S., Deniz, G., Valenta, R., Fiebig, H., Kegel, C., Disch, R., Schmidt-Weber, C. B., Blaser, K., Akdis, C. A. (2004). Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells. J. Exp. Med. 199: 1567-1575 [Abstract] [Full Text]  
• Eisenbarth, S. C., Zhadkevich, A., Ranney, P., Herrick, C. A., Bottomly, K. (2004). IL-4-Dependent Th2 Collateral Priming to Inhaled Antigens Independent of Toll-Like Receptor 4 and Myeloid Differentiation Factor 88. J. Immunol. 172: 4527-4534 [Abstract] [Full Text]  
• Nouri-Aria, K. T., Wachholz, P. A., Francis, J. N., Jacobson, M. R., Walker, S. M., Wilcock, L. K., Staple, S. Q., Aalberse, R. C., Till, S. J., Durham, S. R. (2004). Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. J. Immunol. 172: 3252-3259 [Abstract] [Full Text]  
• Gendo, K., Larson, E. B. (2004). Evidence-Based Diagnostic Strategies for Evaluating Suspected Allergic Rhinitis. ANN INTERN MED 140: 278-289 [Abstract] [Full Text]  
• Francis, J. N., Jacobson, M. R., Lloyd, C. M., Sabroe, I., Durham, S. R., Till, S. J. (2004). CXCR1+CD4+ T Cells in Human Allergic Disease. J. Immunol. 172: 268-273 [Abstract] [Full Text]  
• Durham, S. R (2003). Treatment of seasonal allergic rhinitis: Desensitisation for hay fever works. BMJ 327: 1229-1229 [Full Text]  
• Smart, V., Foster, P. S., Rothenberg, M. E., Higgins, T. J. V., Hogan, S. P. (2003). A Plant-Based Allergy Vaccine Suppresses Experimental Asthma Via an IFN-{gamma} and CD4+CD45RBlow T Cell-Dependent Mechanism. J. Immunol. 171: 2116-2126 [Abstract] [Full Text]  
• Radcliffe, M. J, Lewith, G. T, Turner, R. G, Prescott, P., Church, M. K, Holgate, S. T (2003). Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study. BMJ 327: 251-254 [Abstract] [Full Text]  
• Terreehorst, I., Hak, E., Oosting, A. J., Tempels-Pavlica, Z., de Monchy, J. G.R., Bruijnzeel-Koomen, C. A.F.M., Aalberse, R. C., Gerth van Wijk, R. (2003). Evaluation of Impermeable Covers for Bedding in Patients with Allergic Rhinitis. NEJM 349: 237-246 [Abstract] [Full Text]  
• Kline, J. N., Kitagaki, K., Businga, T. R., Jain, V. V. (2002). Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am. J. Physiol. Lung Cell. Mol. Physiol. 283: L170-L179 [Abstract] [Full Text]  
• Varner, A. E. (2002). The Increase in Allergic Respiratory Diseases : Survival of the Fittest?. Chest 121: 1308-1316 [Abstract] [Full Text]  
• Bousquet, J. (2001). Pro: Immunotherapy Is Clinically Indicated in the Management of Allergic Asthma. Am. J. Respir. Crit. Care Med. 164: 2139-2140 [Full Text]  
• Woodruff, P. G., Fahy, J. V. (2001). Asthma: Prevalence, Pathogenesis, and Prospects for Novel Therapies. JAMA 286: 395-398 [Full Text]  
• Nasser, S M S, Ewan, P W (2001). Lesson of the week: Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. BMJ 322: 1589-1591 [Full Text]  
• Kamradt, T., Mitchison, N. A. (2001). Tolerance and Autoimmunity. NEJM 344: 655-664 [Full Text]  
• Till, S. J., Jopling, L. A., Wachholz, P. A., Robson, R. L., Qin, S., Andrew, D. P., Wu, L., van Neerven, J., Williams, T. J., Durham, S. R., Sabroe, I. (2001). T Cell Phenotypes of the Normal Nasal Mucosa: Induction of Th2 Cytokines and CCR3 Expression by IL-4. J. Immunol. 166: 2303-2310 [Abstract] [Full Text]  
• Cohn, L., Herrick, C., Niu, N., Homer, R. J., Bottomly, K. (2001). IL-4 Promotes Airway Eosinophilia by Suppressing IFN-{{gamma}} Production: Defining a Novel Role for IFN-{{gamma}} in the Regulation of Allergic Airway Inflammation. J. Immunol. 166: 2760-2767 [Abstract] [Full Text]  
• Maecker, H. T., Hansen, G., Walter, D. M., DeKruyff, R. H., Levy, S., Umetsu, D. T. (2001). Vaccination with Allergen-IL-18 Fusion DNA Protects Against, and Reverses Established, Airway Hyperreactivity in a Murine Asthma Model. J. Immunol. 166: 959-965 [Abstract] [Full Text]  
• Kay, A.B. (2001). Allergy and Allergic Diseases- Second of Two Parts. NEJM 344: 109-113 [Full Text]  
• Vrtala, S., Akdis, C. A., Budak, F., Akdis, M., Blaser, K., Kraft, D., Valenta, R. (2000). T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet v 1, Induce Blocking Antibodies. J. Immunol. 165: 6653-6659 [Abstract] [Full Text]  
• Lipworth, B. J, White, P. S (2000). Allergic inflammation in the unified airway: start with the nose. Thorax 55: 878-881 [Full Text]  
• Li, J. T (2000). Grass pollen immunotherapy for 3 to 4 years was still effective 3 years after being discontinued. Evid. Based Med. 5: 46-46 [Full Text]  
• Ostergaard, M. S., Witt, K., Longo, G., Barbi, E., Durham, S. R., Walker, S. M., Varga, E.-M. (2000). Clinical Efficacy of Grass-Pollen Immunotherapy. NEJM 342: 58-59 [Full Text]  
• Cohn, L., Homer, R. J., Niu, N., Bottomly, K. (1999). T Helper 1 Cells and Interferon {gamma} Regulate Allergic Airway Inflammation and Mucus Production. J. Exp. Med. 190: 1309-1318 [Abstract] [Full Text]  
• (1999). Persistently Reduced Symptoms After Allergy Shots. JWatch General 1999: 3-3 [Full Text]  
• Adkinson, N. F. (1999). Immunotherapy for Allergic Rhinitis. NEJM 341: 522-524 [Full Text]